Member Info for Bermudashorts

re. your 18.31- sorry, I should have been clearer. When I say sat and waited, I mean purely in terms of the product development.

Bob - I'm not sure it's true to say that we were let down by Ichor or that the BOD have no responsibility for where Scancell find themselves today. Let's not forget that Scancell simply sat and waited for 2 and a half years for Ichor to even submit their master file to the FDA and have spent another 18 months to 2 years trying to get the IND cleared. The price they have paid for sticking with the Ichor mark II device is nearly 4 years delay, the loss of Keith Flaherty as Principal Investigator, the issues with the cost of Keytruda , the long decline in share price and loss of sentiment. I'm sorry but it's unbelievable that we find ourselves in November 2019 without a single patient being dosed and just one trial centre in Nottingham.

You have built up a significant holding - the size of which is usually limited to institutional investors in an early stage, baby bio. Obviously it goes without saying that is entirely your choice but you really shouldn't advising others to buy.

Where did the LD quote in your 18.17 come from?

Coincidently I'm staying at that very hotel for the couple of days immediately prior to the Investival conference.

Well let's hope for some clarity in due course.

Re. your 15.56 -

No swearing from me. Fortunately I can't hear what any of them are saying atm, I'm staying put in this bunker until 11pm tonight, just in case. :)

Crumbs, thanks for sharing. This sentence re. Modi1 stood out:-

'Scancell will be monitoring Tcell responses before and after immunisation to better understand concomitant therapy to optimise response.'

What does he mean? Is he talking about the Modi1 clinical trial itself? If so, that means the objective of the trial will be to understand the immune response to Modi1 sufficiently to identify combination therapies for future trials. Or is he talking about the current, ongoing preclinical research? If so, does that mean the Modi1 trial will be a combination trial?

The word 'combination' has been creeping into presentations, Trinity Delta reports etc. and there was the recent abstract regarding the possible need for neutralization of T-regs but unless I've missed it (very possible) Scancell have not previously stated that Modi1 will be developed as anything other than a monotherapy.

Perhaps I'm misunderstanding CH's reply to you.

It will have to be either Ursula Ney or Martin Diggle. By the way, JC is already a member of all 3 committees.

Yep good luck to Matthew Frohn.

He was chariman of the Audit Committee and a member of the Remunerations and Nominations Committees. Who is taking his place?

Interview with AN following today's RNS

https://angleplc.com/investor-relations/media/

...........because it hasn't been granted yet.

Thanks for that - good spot.

Also appears to be some progress on the DNA version of the European Moditope patent. Amended claims have now been examined and examiners report sent to Scancell - although they require some further amendments, it looks like most, if not all of the amended claims will be allowable.

https://register.epo.org/application?number=EP17194251&lng=en&tab=doclist

Chelsea,

Sorry I'm not with you. The reason they haven't dosed any patients yet is because none so far have met the recruitment criteria. Please don't worry that Scancell are delaying treatment for any patients - they're not, there are no patients who have met recruitment criteria and are just waiting to be dosed.

No we don't know whether it has been resubmitted but I doubt it. Are you on twitter Crumbs?

Thanks for the reply Crumbs. Agree with you on most things but can we be sure that the FDA haven't been helpful? They certainly haven't cleared the IND but for all we know, that may be entirely down to Ichor/Scancell.

Worth remembering that we were originally told by Scancell that this trial would start in H2 2016 and yet Ichor didn't even submit their master file to the FDA until Feb 2018 and Scancell didn't submit the IND until July 2018. So a full 2 years of the delay here was spent waiting for FDA submission and was entirely down to Scancell and Ichor. The 2016 start date was clearly never going to happen.

Crumbs why don't you trust the FDA?

...........but Chelsea they won't be delaying treatment. Patients are screened and either meet the recruitment criteria or don't. If they do, they'll enter the trial and be treated with SCIB1/Keytruda and if they don't, they won't join the trial and will just be treated with just the SOC treatment of Keytruda. Either way, they'll be treated straight away.

Chelsea,

What doesn't sound right?

By the way, above isn't a loaded question, I'm genuinely interested in what your concerns are.

The fact that AZN's trial was recruiting from over 150 trial centres across 18 countries explains the speed of recruitment. Also the combination and SOC drug was chemo and I assume that many more patients are prescribed chemo as 1st line treatment for lung cancer rather than Keytruda , so a larger patient population to draw from too.

Re. SCIB1, although it's not very clear, if you listen to the Q&A section of the AGM, the BOD did a bit more than just nod- they definitely confirmed they would RNS the first patient dosed.

Yes, I think you're right. From memory there was some discussion about it in one of the research papers and the conclusion was that Moditope shouldn't exacerbate or trigger AI diseases.